Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis

Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis

Approved adjuvant treatment options for stage III melanoma are the immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab, and in presence of a BRAF V600E/K mutation additionally dabrafenib in combination with trametinib (BRAFi/MEKi). This study aims to describe prescription patterns and rec...

Full description

Bibliographic Details
Main Authors: Michèle Hoffmann, Stefanie Hayoz, Berna C. Özdemir
Format: Article
Language:English
Published: MDPI AG 2022-03-01
Series:Biology
Subjects:
melanoma
adjuvant treatment
BRAF inhibitor
anti-PD1
immune checkpoint inhibitor
prescription pattern
Online Access:https://www.mdpi.com/2079-7737/11/3/422

Internet

https://www.mdpi.com/2079-7737/11/3/422

Similar Items